Diffuse Large B-Cell Lymphoma: Clinical Trials

5 trials for Diffuse Large B-Cell Lymphoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 terminated. 5 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 35Terminated 5
Phase 21Terminated 1

Follow Diffuse Large B-Cell Lymphoma: new trials by email Literature Review of Diffuse Large B-Cell Lymphoma trials Research Report on Diffuse Large B-Cell Lymphoma

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL)
JHL1101, MabThera - Diffuse Large B-Cell Lymphoma
Phase 3TerminatedJHL Biotech, Inc.82018-11-132020-01-09
Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
Avelumab, Utomilumab, Rituximab - Diffuse Large B-Cell Lymphoma
Phase 3TerminatedPfizer292016-12-162020-12-17
Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma
Ublituximab, Umbralisib, Bendamustine - Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Phase 2 / Phase 3TerminatedTG Therapeutics, Inc.7102016-05-252022-07-21
Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy
Zevalin, Y-90-Zevalin, Rituximab - Diffuse Large B-cell Lymphoma, Follicle Center Lymphoma
Phase 3TerminatedSpectrum Pharmaceuticals, Inc792012-04-192021-12-16
A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)
Rituximab, Obinutuzumab, Cyclophosphamide - Diffuse Large B-Cell Lymphoma
Phase 3TerminatedHoffmann-La Roche14182011-07-262019-04-12

Narrower conditions

Lymphoma, Large B-Cell, Diffuse (5)  ·  Lymphoma, Follicular (2)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (1)  ·  Lymphoma, B-Cell, Marginal Zone (1)  ·  Lymphoma, Mantle-Cell (1)  ·  Lymphoma, Non-Hodgkin (1)

Broader conditions

Hemic and Lymphatic Diseases (5)  ·  Immune System Diseases (5)  ·  Immunoproliferative Disorders (5)  ·  Lymphatic Diseases (5)  ·  Lymphoma (5)  ·  Lymphoma, B-Cell (5)  ·  Lymphoproliferative Disorders (5)  ·  Neoplasms (5)  ·  Neoplasms by Histologic Type (5)  ·  Lymphoma, Non-Hodgkin (4)  ·  Chronic Disease (1)  ·  Disease Attributes (1)  ·  Hematologic Diseases (1)  ·  Leukemia (1)  ·  Leukemia, B-Cell (1)

Interventions

Rituximab (4)  ·  Bendamustine Hydrochloride (2)  ·  Azacitidine (1)  ·  Cyclophosphamide (1)  ·  Doxorubicin (1)  ·  Gemcitabine (1)  ·  Oxaliplatin (1)  ·  Prednisone (1)  ·  Vincristine (1)  ·  avelumab (1)  ·  ibritumomab tiuxetan (1)  ·  obinutuzumab (1)  ·  ublituximab (1)  ·  umbralisib (1)  ·  utomilumab (1)

Sponsors

Hoffmann-La Roche (1)  ·  JHL Biotech, Inc. (1)  ·  Pfizer (1)  ·  Spectrum Pharmaceuticals, Inc (1)  ·  TG Therapeutics, Inc. (1)

Countries

Australia (4)  ·  Italy (4)  ·  Spain (4)  ·  United Kingdom (4)  ·  United States (4)  ·  Poland (3)  ·  South Korea (3)  ·  Austria (2)  ·  Belgium (2)  ·  Canada (2)  ·  China (2)  ·  Israel (2)  ·  Slovakia (2)  ·  Argentina (1)  ·  Brazil (1)

Top investigators

Jun Zhu, MD/PhD (1)  ·  Owen A O'Connor, MD, PhD (1)

Results publications

PMID 30341058, PMID 30617197, PMID 30770362, PMID 31053601, PMID 32505213, PMID 33054054, PMID 33651099, PMID 33683917, PMID 34323957, PMID 34323958, PMID 34687398, PMID 35962459, PMID 37702406, PMID 38498084, PMID 38843483, PMID 39962481, PMID 42699559

NIH funding

2016 (1)